#### Edgar Filing: Horizon Pharma plc - Form 4

| Horizon Pha   | rma plc                                   |             |   |   |            |                                       |  |   |   |                    |  |
|---|---|-------------|---|---|------------|---------------------------------------|--|---|---|--------------------|--|
| Form 4  |   |             |   |   |            |                                       |  |   |   |                    |  |
| April 11, 201   | .6  |             |   |   |            |                                       |  |   |   |                    |  |
| FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION                                     |   |             |   |   |            |                                       | т  | PPROVAL   |   |                    |  |
| Check this box  |   |             |   |   |            |                                       | LUMINIISSIUN   | OMB<br>Number:  | 3235-0287   |                    |  |
| if no long  | er  |             |   |   |            |                                       |  |   | Expires:  | January 31<br>2005 |  |
| subject to STATEMENT OF CHANGES IN BENEFICIAL OWNERS<br>Section 16. SECURITIES<br>Form 4 or |   |             |   |   | NERSHIP OF | Estimated a<br>burden hou<br>response | average<br>Irs per   |   |   |                    |  |
| Form 5<br>obligatior<br>may conti<br><i>See</i> Instru<br>1(b).                             | inue. Section 1                           | 7(a) of the |   | ility Hold  | ling Con   | ipany                                 | Act o  | ge Act of 1934,<br>f 1935 or Sectio<br>40   | n   |                    |  |
| (Print or Type R  | Responses)                                |             |   |   |            |                                       |  |   |   |                    |  |
| CURTIS GEOFFREY M. Symbol   |   |             |   | suer Name <b>and</b> Ticker or Trading<br>ol<br>zon Pharma plc [HZNP] |            |                                       |  | 5. Relationship of Reporting Person(s) to<br>Issuer   |   |                    |  |
| (Last)  | (First)                                   | (Middle)    | 3. Date of Earliest Transaction   |   |            |                                       | (Cheo  | Check all applicable)   |   |                    |  |
|   |   |             |   | nth/Day/Year)   |            |                                       |  | Director 10% Owner<br>X Officer (give title Other (specify<br>below)<br>SVP, Corporate Communications |   |                    |  |
|   |   |             | endment, Date Original<br>onth/Day/Year)  |   |            |                                       | <ul> <li>6. Individual or Joint/Group Filing(Check<br/>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul> |   |   |                    |  |
| DUBLIN, L   | 24  |             |   |   |            |                                       |  | Person  | More than One Re  | eporting           |  |
| (City)  | (State)                                   | (Zip)       | Table   | e I - Non-D   | erivative  | Secur                                 | ities Aco  | quired, Disposed o  | f, or Beneficial  | lly Owned          |  |
| 1.Title of<br>Security<br>(Instr. 3)  | urity (Month/Day/Year) Execution Date, if |             | 3. 4. Securities Acquired<br>Transaction(A) or Disposed of<br>Code (D)<br>(Instr. 8) (Instr. 3, 4 and 5)<br>(A)<br>or |   |            |                                       | Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)   | 6. Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 4)                                  | p 7. Nature of<br>t Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |                    |  |
|   |   |             |   | Code V  | Amount     | (D)                                   | Price  | (Instr. 3 and 4)  |   |                    |  |
| Ordinary<br>Shares  | 04/08/2016                                |             |   | М   | 7,000      | Α                                     | <u>(1)</u>   | 7,258   | D   |                    |  |
| Ordinary<br>Shares  | 04/08/2016                                |             |   | F   | 2,177      | D                                     | \$<br>18.8   | 5,081   | D   |                    |  |
| Ordinary<br>Shares  |   |             |   |   |            |                                       |  | 420   | Ι   | By Spouse          |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of<br/>information contained in this form are not<br/>required to respond unless the formSEC 1474<br/>(9-02)

#### Edgar Filing: Horizon Pharma plc - Form 4

# displays a currently valid OMB control number.

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. 5. Number<br>Transaction Derivative<br>Code Securities<br>(Instr. 8) Acquired<br>(A) or<br>Disposed of<br>(D)<br>(Instr. 3, 4,<br>and 5) |         | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount<br>of Underlying<br>Securities<br>(Instr. 3 and 4) |  | 8. Pri<br>Deriv<br>Secu<br>(Instr |
|---|---|---|---|---|---------|--|--------------------|--|--|-----------------------------------|
|   |   |   |   | Code V  | (A) (D) | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of<br>Shares |                                   |
| Restricted<br>Stock<br>Units                        | (1)   | 04/08/2016                              |   | М   | 7,000   | (2)  | (2)                | Ordinary<br>Shares   | 7,000                                  | \$                                |

### **Reporting Owners**

| Reporting Owner Name / Address  |            | Relationships |                                  |       |  |  |  |
|---|------------|---------------|----------------------------------|-------|--|--|--|
|   | Director   | 10% Owner     | Officer                          | Other |  |  |  |
| CURTIS GEOFFREY M.<br>C/O HORIZON PHARMA PLC<br>CONNAUGHT HOUSE, 1ST FL, 1 BURLIN<br>RD<br>DUBLIN, L2 4 | GTON       |               | SVP, Corporate<br>Communications |       |  |  |  |
| Signatures  |            |               |                                  |       |  |  |  |
| /s/ Paul W. Hoelscher,<br>Attorney-in-Fact  | 04/11/2016 |               |                                  |       |  |  |  |

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

- (1) Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- (2) On April 8, 2015 and May 1, 2015, the reporting person was granted an aggregate of 28,000 restricted stock units. The restricted stock units vest in four equal annual installments beginning on April 8, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.